Saturday 17 October 2026
Export ZYME’s income statement to Excel — free account
Zymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.
25.07
0.68
−2.64%
Follow ZYME
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
7 | 4 | 3 | 8 | 2 | 4 | 2 | 4 | 7 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 4.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
11.56 | 2.59 | 2.15 | 2.90 | 0.07 | 9.64 | 6.83 | 3.79 | 5.95 | — |
P/S ratio |
18.74 | 14.55 | 9.40 | 1.19 | 31.67 | 61.13 | 58.51 | 8.05 | 3.26 | 15.62 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 3.75 | 0.00 | 0.00 | 0.00 | 20.57 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(3.24) | (1.97) | 2.84 | 6.41 | (3.93) | 2.66 | 0.86 | 4.79 | 8.59 | (1.28) |
Beneish M-Score |
— | — | — | 2.12 | — | — | — | — | (7.25) | — |
P/Operating CF |
(193.53) | (26.75) | 51.23 | 1.50 | (16.73) | (49.71) | (47.55) | 8.52 | 4.32 | (13.50) |
P/B ratio |
7.39 | 3.28 | 1.54 | 1.00 | 3.39 | 5.81 | 7.04 | 2.37 | 1.45 | 0.00 |
Price to Tangible BV |
7.78 | 3.45 | 1.61 | 1.04 | 3.62 | 6.06 | 7.59 | 2.56 | 1.63 | 0.00 |
EV/Sales |
16.58 | 11.89 | 4.78 | 0.06 | 23.37 | 50.34 | 48.58 | 4.36 | 1.65 | 13.59 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(53.23) | (8.24) | (3.07) | 0.17 | (3.24) | (12.95) | (17.53) | 9.57 | 389.16 | (3.64) |
EV/FCF |
(49.69) | (8.02) | (2.89) | 0.18 | (3.03) | (12.44) | (14.61) | 11.15 | (29.37) | (3.16) |
Quick Ratio |
5.52 | 3.19 | 7.06 | 5.50 | 3.73 | 5.16 | 3.65 | 6.69 | 6.15 | 2.69 |
Current Ratio |
5.88 | 3.40 | 7.41 | 5.70 | 4.01 | 5.31 | 3.78 | 6.82 | 6.30 | 2.81 |
Net Debt/EBITDA |
2.81 | 1.79 | 3.10 | (3.57) | 1.23 | 2.41 | 2.08 | 6.73 | 14.03 | 0.97 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4.70% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 |
Asset Turnover |
0.26 | 0.15 | 0.12 | 0.79 | 0.06 | 0.09 | 0.10 | 0.28 | 0.46 | 0.19 |
Operating CF/Net income |
0.41 | 0.90 | 1.00 | 1.16 | 0.91 | 0.84 | 0.56 | (0.66) | (0.02) | 1.04 |
Capex/Depreciation |
(0.21) | (0.27) | (0.24) | (1.81) | (1.39) | (0.61) | (1.89) | (0.94) | (1.14) | (5.33) |
Interest Coverage |
— | — | — | 36.30 | (109.74) | (32.91) | (25.12) | (9.12) | (21.32) | (39.86) |
| (26.72%) | (30.54%) | (24.78%) | 33.51% | (64.29%) | (55.08%) | (68.25%) | (24.62%) | (17.42%) | (248.22%) | |
| (20.04%) | (23.51%) | (19.30%) | 23.96% | (45.68%) | (39.83%) | (47.48%) | (19.42%) | (9.67%) | (57.72%) | |
ROIC |
(145.69%) | (75.84%) | (95.36%) | 11,267.96% | 0.00% | 0.00% | 0.00% | 0.00% | (19.64%) | (73.91%) |
Return on Tangible Assets |
(36.55%) | (53.39%) | (31.48%) | 26.24% | (88.58%) | (47.32%) | (60.50%) | (20.21%) | (12.88%) | (92.25%) |
Average Days of Receivables |
15.98 | 266.99 | 93.53 | 29.56 | 213.61 | 143.31 | 26.99 | 2.46 | 16.43 | 142.80 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
58.05% | 80.61% | 92.68% | 17.78% | 159.52% | 141.76% | 217.23% | 55.56% | 35.84% | 114.03% |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.03 | 0.03 | 0.04 | 0.03 | 0.05 | 0.06 | 0.10 | 0.14 |
Share Based Compensation of Revenue |
26.46% | 23.32% | 10.66% | 0.97% | 40.31% | 74.75% | 165.84% | 25.35% | 6.62% | 38.98% |
Graham Net Nets |
0.09 | 0.16 | 0.42 | 0.79 | 0.18 | 0.14 | 0.11 | 0.33 | 0.46 | 0.01 |
Graham Number |
0.00 | 0.00 | 0.00 | 17.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(4.10%) | (11.00%) | (16.67%) | 23.61% | (25.08%) | (7.58%) | (8.10%) | (9.20%) | (14.00%) | (27.92%) |
Free Cash Flow Yield |
(1.78%) | (10.19%) | (17.59%) | 26.65% | (24.35%) | (6.62%) | (5.68%) | 4.86% | (1.72%) | (27.58%) |
Revenue per Share |
1.41 | 1.01 | 1.10 | 6.33 | 0.52 | 0.77 | 0.78 | 1.82 | 2.44 | 0.86 |
Operating CF per Share |
(0.44) | (1.45) | (1.72) | 2.21 | (3.73) | (3.01) | (2.15) | 0.83 | 0.01 | (2.77) |
Capex per Share |
(0.03) | (0.04) | (0.06) | (0.20) | (0.26) | (0.12) | (0.36) | (0.12) | (0.15) | (0.43) |
Free Cash Flow per Share |
(0.47) | (1.49) | (1.78) | 2.01 | (3.99) | (3.13) | (2.52) | 0.71 | (0.14) | (3.20) |
Cash per Share |
3.03 | 2.98 | 5.44 | 7.55 | 4.90 | 8.46 | 7.86 | 6.88 | 4.13 | 3.16 |
Shareholders Equity per Share |
3.56 | 4.47 | 6.75 | 7.56 | 4.83 | 8.14 | 6.46 | 6.20 | 5.48 | 5.33 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.56 | 4.47 | 6.75 | 7.56 | 4.83 | 8.14 | 6.46 | 6.20 | 5.48 | 5.33 |
Free Cash Flow |
(35.36) | (113.12) | (122.38) | 130.98 | (205.74) | (157.67) | (95.73) | 20.76 | (2.90) | (40.71) |
Working Capital |
206.45 | 212.16 | 357.16 | 449.08 | 216.37 | 369.41 | 229.28 | 174.38 | 77.67 | 29.93 |
Capital Expenditures |
(2.35) | (3.07) | (4.08) | (13.12) | (13.28) | (6.26) | (13.88) | (3.42) | (3.12) | (5.46) |
Net Current Asset Value |
170.74 | 176.13 | 296.85 | 388.94 | 148.18 | 326.62 | 189.31 | 140.38 | 76.81 | 20.35 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.04 | 0.05 | 0.03 | 0.50 | 0.16 | 0.47 | 0.06 | 0.06 | 0.50 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 3.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.72 | 0.63 | 0.87 | 0.29 | 0.42 | 0.84 | 0.66 | 0.56 | 0.38 | 0.15 |
Cash ROIC |
(7.11%) | (20.04%) | (14.58%) | 13.30% | (41.01%) | (18.85%) | (17.58%) | 5.45% | (1.42%) | (36.17%) |
Accounts Receivable Turnover |
3.51 | 2.03 | 2.88 | 16.83 | 1.73 | 4.46 | 23.24 | 39.45 | 15.60 | 3.35 |
Accounts Payable Turnover |
2.85 | 2.54 | 2.15 | 2.78 | 3.75 | 4.32 | 4.72 | 5.07 | 4.51 | 5.16 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
96.83 | 162.24 | 116.89 | 153.05 | 114.73 | 93.07 | 112.40 | 85.94 | 79.15 | 93.96 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
30.23 | 37.65 | 26.44 | 24.51 | 15.45 | 8.74 | 1.27 | 1.34 | 3.32 | 3.29 |
Average Payables |
48.09 | 52.92 | 66.73 | 75.13 | 53.22 | 39.67 | 24.55 | 11.23 | 9.27 | 7.13 |
Average Assets |
404.81 | 521.99 | 614.80 | 518.93 | 463.75 | 453.29 | 306.34 | 188.22 | 112.98 | 58.57 |
Average Common Equity |
303.63 | 401.79 | 478.88 | 371.03 | 329.51 | 327.80 | 213.09 | 148.46 | 62.72 | 13.62 |
Columns are period end dates